Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Thoracic 1Lymphoid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Cytopenia 1Anemia, Refractory 1

Interventions

fludarabine phosphate 12Whole-Body Irradiation 11Peripheral Blood Stem Cell Transplantation 11Cyclophosphamide 11Mycophenolic Acid 9fludarabine 7Cyclosporine 6Busulfan 6Tacrolimus 4Melphalan 4Filgrastim 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Antilymphocyte Serum 4eltrombopag 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Alemtuzumab 3AP 1903 reagent 3romiplostim 2Transplantation 2Topotecan 2Thiotepa 2Sirolimus 2SRA737 2Radiotherapy 2Gene Expression Profiling 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × ON 01910 × Classical hematology × Clear all
NCT00854945 2017-06-26

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Traws Pharma, Inc.

Phase 1/2 Completed
36 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡